396,247 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Acquired by PFG Investments LLC

PFG Investments LLC acquired a new stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 396,247 shares of the biotechnology company’s stock, valued at approximately $1,312,000.

A number of other hedge funds also recently made changes to their positions in ALDX. Los Angeles Capital Management LLC grew its holdings in Aldeyra Therapeutics by 240.9% during the 1st quarter. Los Angeles Capital Management LLC now owns 380,773 shares of the biotechnology company’s stock valued at $1,245,000 after purchasing an additional 269,061 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of Aldeyra Therapeutics by 106.3% during the first quarter. Acadian Asset Management LLC now owns 452,449 shares of the biotechnology company’s stock valued at $1,478,000 after acquiring an additional 233,169 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Aldeyra Therapeutics during the first quarter worth about $585,000. Panagora Asset Management Inc. acquired a new position in shares of Aldeyra Therapeutics in the second quarter worth about $200,000. Finally, Woodstock Corp boosted its holdings in Aldeyra Therapeutics by 46.3% in the first quarter. Woodstock Corp now owns 170,715 shares of the biotechnology company’s stock valued at $558,000 after purchasing an additional 54,011 shares during the last quarter. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Stock Performance

NASDAQ:ALDX opened at $5.91 on Tuesday. The company has a market capitalization of $351.17 million, a price-to-earnings ratio of -11.59 and a beta of 1.44. Aldeyra Therapeutics, Inc has a one year low of $1.42 and a one year high of $7.42. The stock has a 50-day simple moving average of $4.47 and a 200 day simple moving average of $4.00.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ALDX shares. StockNews.com downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 22nd. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Friday, August 9th.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.